The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Penipanem     (5R,6S)-3-[(3S)-1- ethanimidoylpyrrolidin-3...

Synonyms: panipenem, Panipenemum, PAPM, CHEMBL339323, SureCN150517, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of RS 533


High impact information on RS 533


Chemical compound and disease context of RS 533


Biological context of RS 533


Anatomical context of RS 533


Associations of RS 533 with other chemical compounds


Gene context of RS 533

  • The effect of initial panipenem (CAS No. 87726-17-8) concentration on its degradation in an aqueous solution was investigated [17].

Analytical, diagnostic and therapeutic context of RS 533


  1. Increase in susceptibility of Pseudomonas aeruginosa to carbapenem antibiotics in low-amino-acid media. Fukuoka, T., Masuda, N., Takenouchi, T., Sekine, N., Iijima, M., Ohya, S. Antimicrob. Agents Chemother. (1991) [Pubmed]
  2. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Kojima, S., Nadai, M., Kitaichi, K., Wang, L., Nabeshima, T., Hasegawa, T. Antimicrob. Agents Chemother. (1998) [Pubmed]
  3. In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem. Neu, H.C., Chin, N.X., Saha, G., Labthavikul, P. Antimicrob. Agents Chemother. (1986) [Pubmed]
  4. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Fukuoka, T., Ohya, S., Narita, T., Katsuta, M., Iijima, M., Masuda, N., Yasuda, H., Trias, J., Nikaido, H. Antimicrob. Agents Chemother. (1993) [Pubmed]
  5. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Kimura, T., Sunakawa, K., Matsuura, N., Kubo, H., Shimada, S., Yago, K. Antimicrob. Agents Chemother. (2004) [Pubmed]
  6. Panipenem/betamipron. Goa, K.L., Noble, S. Drugs (2003) [Pubmed]
  7. Biapenem. Perry, C.M., Ibbotson, T. Drugs (2002) [Pubmed]
  8. Decreases of the susceptibility to low molecular weight beta-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of outer membrane protein D2 in their diffusion. Gotoh, N., Nishino, T. J. Antimicrob. Chemother. (1990) [Pubmed]
  9. Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function. Tajima, N., Ishizuka, H., Naganuma, H. Chemotherapy. (2006) [Pubmed]
  10. Isomerization kinetics of panipenem in aqueous solution. Ito, N., Suzuki, M., Kusai, A., Takayama, K. Chem. Pharm. Bull. (2005) [Pubmed]
  11. Interaction of valproic acid and carbapenem antibiotics with multidrug resistance-associated proteins in rat erythrocyte membranes. Ogawa, K., Yumoto, R., Hamada, N., Nagai, J., Takano, M. Epilepsy Res. (2006) [Pubmed]
  12. Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers. Torii, M., Takiguchi, Y., Izumi, M., Fukushima, T., Yokota, M. International journal of pharmaceutics. (2002) [Pubmed]
  13. Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa. Horii, T., Ichiyama, S., Ohta, M., Kobayashi, M. J. Med. Microbiol. (1999) [Pubmed]
  14. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: correlation to concentration in central nervous system. Kurihara, A., Hisaoka, M., Mikuni, N., Kamoshida, K. J. Pharmacobio-dyn. (1992) [Pubmed]
  15. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Horiuchi, M., Kimura, M., Tokumura, M., Hasebe, N., Arai, T., Abe, K. Toxicology (2006) [Pubmed]
  16. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. Kobayashi, Y. J. Infect. Chemother. (2005) [Pubmed]
  17. Effect of initial concentration on stability of panipenem in aqueous solution. Ito, N., Suzuki, M., Kusai, A., Takayama, K. Chem. Pharm. Bull. (2005) [Pubmed]
  18. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study. Hayakawa, M., Ito, Y., Fujita, I., Iseki, K., Gando, S. ASAIO J. (2006) [Pubmed]
  19. Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. Ohashi, N., Uematsu, T., Nagashima, S., Kanamaru, M., Tajima, N., Togawa, A., Hishida, A. J. Infect. Chemother. (2005) [Pubmed]
  20. Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients. Shibuya, Y., Kitamura, S., Tani, G., Fukushima, Y., Yatagai, S., Nakamoto, T., Motojima, S. J. Infect. Chemother. (2002) [Pubmed]
  21. The effect of biliary decompression on antibiotic biliary excretion. Yamamoto, S., Kubota, Y., Takaoka, M., Ogura, M., Tsuji, K., Yanagitani, K., Shimatani, M., Shibatani, N., Imai, Y., Takamidoh, S., Inoue, K. Hepatogastroenterology (2002) [Pubmed]
  22. Quantitative evaluation of effect of renal failure on the pharmacokinetics of panipenem in rats. Tajima, N., Soma, M., Ishizuka, H., Naganuma, H. Biol. Pharm. Bull. (2005) [Pubmed]
WikiGenes - Universities